MedDataX Logo

Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting

NCT ID: NCT03342144

Last Updated: 2025-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-12-04

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia

NCT03415035

Cancer - Chronic Lymphocytic Leukemia
ACTIVE_NOT_RECRUITING

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

NCT04895436

Chronic Lymphocytic Leukemia (CLL)
RECRUITING PHASE2

A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)

NCT04198415

Cancer Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Leukemia (SLL)
COMPLETED

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05105841

Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL)
COMPLETED PHASE2

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

NCT03406156

Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL)
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Lymphocytic Leukemia (CLL)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants Receiving Venetoclax

Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.

No interventions assigned to this group

Participants Receiving Venetoclax + Rituximab

Participants with CLL receiving venetoclax in combination with rituximab.

No interventions assigned to this group

Participants Receiving Venetoclax + Obinutuzumab

Participants with CLL receiving venetoclax in combination with obinutuzumab.

No interventions assigned to this group

Participants Receiving Venetoclax + Ibrutinib

Participants with CLL receiving venetoclax in combination with ibrutinib.

No interventions assigned to this group

Participants Receiving Venetoclax + Acalabrutinib

Participants with CLL receiving venetoclax in combination with acalabrutinib.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment.

Exclusion Criteria

\- None
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universitaetsklinikum St. Poelten /ID# 221152

Sankt Pölten, Lower Austria, Austria

Site Status RECRUITING

Medizinische Universitaet Graz /ID# 221155

Graz, Styria, Austria

Site Status COMPLETED

Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 221153

Salzburg, , Austria

Site Status ACTIVE_NOT_RECRUITING

Hanusch Krankenhaus /ID# 221151

Vienna, , Austria

Site Status COMPLETED

Stauferklinikum Schwaebisch Gmuend /ID# 201518

Mutlangen, Baden-Wurttemberg, Germany

Site Status COMPLETED

Onkologische Praxis /ID# 201545

Stuttgart, Baden-Wurttemberg, Germany

Site Status COMPLETED

Schwarzwald-Baar-Klinikum /ID# 208176

Villingen-Schwenningen, Baden-Wurttemberg, Germany

Site Status ACTIVE_NOT_RECRUITING

MVZ am Klinikum Aschaffenburg Onkologie /ID# 201548

Aschaffenburg, Bavaria, Germany

Site Status ACTIVE_NOT_RECRUITING

Studienzentrum Aschaffenburg /ID# 204125

Aschaffenburg, Bavaria, Germany

Site Status ACTIVE_NOT_RECRUITING

Gemeinschaftspraxis Dr. Heinrich und Prof. Bangerter /ID# 200950

Augsburg, Bavaria, Germany

Site Status COMPLETED

Drs. Tanzer, Chirca, Stoeberl /ID# 202613

Bad Reichenhall, Bavaria, Germany

Site Status COMPLETED

Internistische Schwerpunktpraxen, Erlangen /ID# 200949

Erlangen, Bavaria, Germany

Site Status COMPLETED

Onkologie Hof /ID# 201531

Hof, Bavaria, Germany

Site Status COMPLETED

Praxis Dr. Stauch /ID# 202611

Kronach, Bavaria, Germany

Site Status ACTIVE_NOT_RECRUITING

VK&K Studien GbR /ID# 202614

Landshut, Bavaria, Germany

Site Status ACTIVE_NOT_RECRUITING

Haemato-Onkologie /ID# 205236

Munich, Bavaria, Germany

Site Status ACTIVE_NOT_RECRUITING

Praxis Dr. Kreher /ID# 202604

Bad Liebenwerda, Brandenburg, Germany

Site Status ACTIVE_NOT_RECRUITING

Praxis Dres. Kiehl/Stein /ID# 210052

Frankfurt (Oder), Brandenburg, Germany

Site Status COMPLETED

MVZ f. Blut- u.Krebserkrankungen /ID# 206704

Potsdam, Brandenburg, Germany

Site Status ACTIVE_NOT_RECRUITING

Ambulantes Tumorzentrum Bremerhaven /ID# 224353

Bremerhaven, City state Bremen, Germany

Site Status COMPLETED

Centrum fuer Haematologie und Onkologie Bethanien /ID# 206701

Frankfurt am Main, Hesse, Germany

Site Status ACTIVE_NOT_RECRUITING

MVZ Dres. Cordes & Partner /ID# 202598

Frankfurt am Main, Hesse, Germany

Site Status ACTIVE_NOT_RECRUITING

Klinikum Frankfurt Hoechst /ID# 210048

Frankfurt am Main, Hesse, Germany

Site Status COMPLETED

Praxis Dres. Tebbe/Mayer /ID# 206730

Kassel, Hesse, Germany

Site Status ACTIVE_NOT_RECRUITING

Onkologische Kooperation Harz /ID# 201550

Goslar, Lower Saxony, Germany

Site Status ACTIVE_NOT_RECRUITING

OAZ Hannover /ID# 201538

Hanover, Lower Saxony, Germany

Site Status ACTIVE_NOT_RECRUITING

Onkolologische Praxis Oldenburg /ID# 202607

Oldenburg, Lower Saxony, Germany

Site Status ACTIVE_NOT_RECRUITING

MVZ der Paracelsus-Klinik /ID# 201541

Osnabrück, Lower Saxony, Germany

Site Status COMPLETED

Med. Studiengesellschaft Nord West GmbH /ID# 201535

Westerstede, Lower Saxony, Germany

Site Status COMPLETED

Praxis Dres. Plewe/Losem /ID# 202606

Neuss, North Rhine-Westphalia, Germany

Site Status ACTIVE_NOT_RECRUITING

Hämatologie und Onkologie /ID# 205247

Kaiserslautern, Rhineland-Palatinate, Germany

Site Status ACTIVE_NOT_RECRUITING

Praxis Dr. Klaproth/Cura /ID# 216413

Neunkirchen, Saarland, Germany

Site Status COMPLETED

Onkozentrum Dresden /ID# 202599

Dresden, Saxony, Germany

Site Status ACTIVE_NOT_RECRUITING

BAG Freiberg-Richter, Jacobasch, Illmer, Wolf /ID# 201532

Dresden, Saxony, Germany

Site Status COMPLETED

Luebecker Oncology Practice /ID# 200952

Lübeck, Schleswig-Holstein, Germany

Site Status COMPLETED

Friedrich-Ebert-Krankenhaus GmbH /ID# 206206

Neumünster, Schleswig-Holstein, Germany

Site Status ACTIVE_NOT_RECRUITING

Praxis Dres. Krober/Stosiek /ID# 206729

Regensburg, State of Berlin, Germany

Site Status ACTIVE_NOT_RECRUITING

Caritas-Krankenhaus gGmbH /ID# 243212

Bad Mergentheim, , Germany

Site Status COMPLETED

MVZ Klinikum Mittelbaden GmbH /ID# 206207

Baden-Baden, , Germany

Site Status COMPLETED

Praxis für Hämatologie und Onkologie /ID# 241763

Berlin, , Germany

Site Status COMPLETED

Onkologische Schwerpunktpraxis /ID# 200953

Berlin, , Germany

Site Status COMPLETED

Praxis am Volkspark /ID# 243195

Berlin, , Germany

Site Status COMPLETED

Onkologie am Segelfliegerdamm /ID# 202603

Berlin, , Germany

Site Status COMPLETED

Pioh Dres. Draube & Partner /ID# 239507

Cologne, , Germany

Site Status COMPLETED

Praxis Dres. Prange-Krex/Mohm /ID# 210049

Dresden, , Germany

Site Status ACTIVE_NOT_RECRUITING

St. Georg Klinikum Eisenach gemeinnützige GmbH (GKE) /ID# 250200

Eisenach, , Germany

Site Status COMPLETED

Praxis fuer interdisziplinaere Onkolologie und Haematologie /ID# 206999

Freiburg im Breisgau, , Germany

Site Status ACTIVE_NOT_RECRUITING

MVZ Onkologie GmbH /ID# 212376

Hagen, , Germany

Site Status COMPLETED

onkomedic GbR /ID# 218354

Halle, , Germany

Site Status COMPLETED

OncoResearch Lerchenfeld GmbH /ID# 205237

Hamburg, , Germany

Site Status ACTIVE_NOT_RECRUITING

Onkologische Gemeinschaftspraxis /ID# 205239

Hamburg, , Germany

Site Status ACTIVE_NOT_RECRUITING

Evangelisches Krankenhaus Hamm /ID# 206703

Hamm, , Germany

Site Status ACTIVE_NOT_RECRUITING

Studienzentrum am Raschplatz /ID# 250180

Hanover, , Germany

Site Status COMPLETED

Studienbüro Kamal und Dorn GBR /ID# 234105

Hanover, , Germany

Site Status COMPLETED

Klinikum Idar-Oberstein GmbH /ID# 210046

Idar-Oberstein, , Germany

Site Status ACTIVE_NOT_RECRUITING

Praxis Fuchs/Koehler /ID# 243215

Langenhessen, , Germany

Site Status COMPLETED

Bruederkrankenhaus St. Josef Paderborn /ID# 202600

Paderborn, , Germany

Site Status COMPLETED

Onkologische Praxis GbR /ID# 206705

Porta Westfalica, , Germany

Site Status ACTIVE_NOT_RECRUITING

Praxis Dres. Decker/Lakner/Leithäuser /ID# 206208

Rostock, , Germany

Site Status ACTIVE_NOT_RECRUITING

Diakonieklinikum Schwaebisch Hall /ID# 206205

Schwäbisch Hall, , Germany

Site Status ACTIVE_NOT_RECRUITING

MVZ am Schlossgarten GmbH /ID# 210043

Schwetzingen, , Germany

Site Status COMPLETED

Kantonsspital Aarau AG /ID# 210034

Aarau, Canton of Aargau, Switzerland

Site Status COMPLETED

Spital Thun /ID# 233714

Thun, Canton of Bern, Switzerland

Site Status COMPLETED

Luzerner Kantonsspital /ID# 210029

Lucerne, Canton of Lucerne, Switzerland

Site Status COMPLETED

Réseau Hospitalier Neuchâtelois /ID# 227865

Neuchâtel, Canton of Neuchâtel, Switzerland

Site Status RECRUITING

Kantonsspital St. Gallen /ID# 223037

Sankt Gallen, Canton of St. Gallen, Switzerland

Site Status COMPLETED

KSW Kantonsspital Winterthur /ID# 211068

Winterthur, Canton of Zurich, Switzerland

Site Status COMPLETED

EOC Ospedale Regionale di Bellinzona e Valli /ID# 208782

Bellinzona, Canton Ticino, Switzerland

Site Status COMPLETED

Kantonsspital Münsterlingen /ID# 210035

Münsterlingen, Thurgau, Switzerland

Site Status COMPLETED

Inselspital, Universitaetsspital Bern /ID# 210031

Bern, , Switzerland

Site Status COMPLETED

Countries

Review the countries where the study has at least one active or historical site.

Austria Germany Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Johannes Huelsenbeck

Role: CONTACT

[email protected]
+49 611-1720-3036

Stefan Lorenz

Role: CONTACT

[email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Schwaner I, Kuhn T, Losem C, Wolff T, Otremba B, Zaiss M, Hulsenbeck J, Famulla K, Nosslinger T, Rossi D. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study. Ann Hematol. 2024 Jun;103(6):2013-2020. doi: 10.1007/s00277-024-05638-7. Epub 2024 Feb 29.

Reference Type DERIVED
PMID: 38421404 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.rxabbvie.com/

Related Info

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P17-132

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice
NCT03310190 COMPLETED
A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
NCT03659669 SUSPENDED
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
NCT02242942 COMPLETED PHASE3
A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)
NCT02756611 COMPLETED PHASE3
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
NCT02758665 COMPLETED PHASE2
A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom
NCT05555979 COMPLETED
A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice
NCT04178317 COMPLETED
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
NCT03319901 RECRUITING PHASE1/PHASE2
Venetoclax and Ibrutinib in Treating in Participants with Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
NCT03513562 ACTIVE_NOT_RECRUITING PHASE2
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02966756 RECRUITING PHASE2
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
NCT05246345 RECRUITING
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
NCT06362044 COMPLETED
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
NCT02141282 COMPLETED PHASE2
Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia
NCT03455517 COMPLETED PHASE2
A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia
NCT03873493 COMPLETED PHASE2
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048 ACTIVE_NOT_RECRUITING PHASE3
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
NCT02980731 COMPLETED PHASE3
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05057494 ACTIVE_NOT_RECRUITING PHASE3
A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece
NCT04159779 ACTIVE_NOT_RECRUITING
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
NCT02910583 COMPLETED PHASE2
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
NCT03701282 ACTIVE_NOT_RECRUITING PHASE3
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT03986034 RECRUITING PHASE2
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
NCT05182385 ACTIVE_NOT_RECRUITING PHASE1/PHASE2
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
NCT01685892 COMPLETED PHASE1
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
NCT04282811 RECRUITING